


eISSN: 2251-7308

pISSN: 2228-5881

Advanced Pharmaceutical Bulletin



Official Journal of
Faculty of Pharmacy
&

Drug Applied Research Center
Tabriz University of Medical Sciences

APB

Quarterly

<http://apb.tbzmed.ac.ir>
apb@tbzmed.ac.ir

Advanced Pharmaceutical Bulletin

(/)

ISSN: 2228-5881 (<https://portal.issn.org/resource/ISSN/2228-5881>) eISSN: 2251-7308 (<https://portal.issn.org/resource/ISSN/2251-7308>)

Editors



Hadi Valizadeh (PharmD, PhD)

Founder and Editor-in-chief

Professor of Pharmaceutics

Faculty of Pharmacy,

Tabriz University of Medical Sciences, Tabriz, IRAN

Office Phone: +98(41)33348801

Email: valizadeh@tbzmed.ac.ir (<mailto:valizadeh@tbzmed.ac.ir>)

Google scholar (<http://scholar.google.com/citations?user=j1p6wZ4AAAAJ&hl=en>)



Hossein Babaei (PhD)

Director-in-Charge

Professor of Pharmacology

Faculty of Pharmacy,

Tabriz University of Medical Sciences

Tabriz, IRAN

Office Phone: +98(41)33363311

Fax: +98 (41) 33363231

E-mail: babaeih@tbzmed.ac.ir (<mailto:babaeih@tbzmed.ac.ir>)

(<https://scholar.google.com/citations?user=LpGJ520AAAAJ&hl=en>) Google Scholar (<https://scholar.google.com/citations?user=LpGJ520AAAAJ&hl=en>)

Associate Editors



Parvin Zakeri-Milani, Ph.D

Faculty of Pharmacy Tabriz University of Medical Sciences
Tabriz, IRAN
Phone: +98(41)33341315
E-mail: pzakeri@tbzmed.ac.ir (mailto:pzakeri@tbzmed.ac.ir)
Google scholar (<https://scholar.google.com/citations?user=zChcMrn07hoC&hl=en>)



Hojjatollah Nozad Charoudeh

Associate Professor of Stem Cell Biology
Faculty of Medicine, Tabriz University of Medical Sciences
Tabriz, Iran,
Email: nozadh@tbzmed.ac.ir
Tel: +98(41)33342086
Google scholar (<https://scholar.google.com/citations?user=pgLFTBAAAAAJ&hl=en>)



Afshin Gharekhani

Department of Clinical Pharmacy,
Faculty of Pharmacy,
Tabriz University of Medical Sciences
Tabriz, IRAN
Email: Gharekhania@tbzmed.ac.ir (mailto:Gharekhania@tbzmed.ac.ir)
Google scholar (<https://scholar.google.com/citations?user=4aUxAV4AAAAJ&hl=en>)



Jafar Ezzati Nazhad Dolatabadi (PhD)

Assistant Professor of Pharmaceutical Nanotechnology
Tabriz University of Medical Sciences
Tabriz, IRAN
Email: ezzatij@tbzmed.ac.ir (mailto:ezzati@tbzmed.ac.ir)
Google scholar (<https://scholar.google.com/citations?user=Hdi1uF8AAAAJ&hl=en>)



Saurabh Bhatia (PhD)

Associate Professor,
Amity Institute of Pharmacy (AIP), Amity university,
Manesar, Gurgaon, INDIA
Tel.: 0091-9991634366
Email: sbhatia@ggn.amity.edu (mailto:sbhatia@ggn.amity.edu)
Google scholar (https://scholar.google.com/citations?user=C__7sY4AAAAJ&hl=en), linkedin (<https://www.linkedin.com/in/dr-saurabh-bhatia-65750b1a/>)



Hamed Hamishehkar, Ph.D

Professor of Pharmaceutics
Drug applied research center,
Tabriz University of Medical Sciences, Tabriz, IRAN
Tel: +98(41)-33378163
Email: hamishehkar.hamed@gmail.com (mailto:hamishehkar.hamed@gmail.com)
Google scholar (https://scholar.google.com/citations?hl=en&user=le6cgp4AAAAJ&view_op=list_works&sortby=pubdate)

International Editorial and Advisory Board



Raimar Loebenber, PhD

Professor, Pharmaceutical Sciences
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta
3-142J Katz Group Centre, Edmonton, AB, Canada
Email: raimar.loebenberg@ualberta.ca (mailto:rloebenberg@pharmacy.ualberta.ca)
Tel: +1 (780) 492-1255
Google scholar, (<http://scholar.google.com/citations?user=wP6VnFMAAAj&hl=en>) LinkedIn (<http://www.linkedin.com/pub/raimar-loebenberg/5b/5bb/a66>)



Gabriele Caviglioli, PhD

Professor at Università degli Studi di Genova
via Brigata Salerno, 13, 16147 Genova, Italy
Email: caviglioli@difar.unige.it (mailto:caviglioli@difar.unige.it)
LindedIn (<https://www.linkedin.com/in/gabriele-caviglioli-aa125116/>)



Hamid Omidian, PhD

Associate Professor, Pharmaceutical Sciences
Nova Southeastern University
3200 S University Drive
Fort Lauderdale, FL 33328, USA
Email: omidian@nova.edu (mailto:omidian@nova.edu)
Tel: 954-262-1334
Google scholar (<http://scholar.google.com/citations?hl=en&user=vWT5lowAAAAj>)



Mohammad Barzegar Jalali, Ph.D

Professor of Pharmaceutics
Faculty of Pharmacy,
Tabriz University of Medical Sciences, Tabriz, IRAN
Office Phone: +98(41)33376148
Fax: +98 (41)33344798
E-mail: barzegar_jalali@yahoo.com (mailto:barzegar_jalali@yahoo.com)
Google scholar (<https://scholar.google.com/citations?user=ozaHfhkAAAAj&hl=en>)



Miguel de la Guardia, PhD

Professor of Analytical Chemistry
Department of Analytical Chemistry
University of Valencia,
Valencia, SPAIN
Scopus ID: 7006639927
Email: miguel.delaguardia@uv.es (email: miguel.delaguardia@uv.es)
Google scholar (https://scholar.google.com/citations?hl=en&user=3oOU98IAAAAj&view_op=list_works&sortby=pubdate)



Ali Nokhodchi, PhD

Professor of Pharmaceutics and Drug Delivery
School of Life Sciences (<http://www.sussex.ac.uk/profiles/355690>)
University of Sussex
Brighton, UK BN1 9QG
email: A.Nokhodchi@sussex.ac.uk (<http://apb.tbzmed.ac.ir/AboutJournal/EditorialBoard/tabid/76/ct/Edit/mid/398/A.Nokhodchi@sussex.ac.uk>)
Google scholar (<http://scholar.google.com/citations?user=LiWqf28AAAAj&hl=en>)



Yadollah Omid (PharmD, PhD)

Professor of Pharmaceutical Sciences
College of Pharmacy, Nova Southeastern University
Fort Lauderdale, FL, USA
Email: yomidi@yahoo.com (mailto:yomidi@yahoo.com)
Google Scholar (<http://scholar.google.com/citations?user=xBc5Y1YAAAAj&hl=en>)



Mehrdad Hamidi, Ph.D

Professor of Pharmaceutics
Faculty of Pharmacy, Zanjan University of Medical Sciences
Zanjan, IRAN
Email: hamidim@zums.ac.ir (mailto:hamidim@zums.ac.ir)
Google scholar (<http://scholar.google.com/citations?user=S5gjK9sAAAAJ&hl=en>)



Gabriel Hancu, PhD

Associate professor (<http://www.umftgm.ro/facultatea-de-farmacie/departamente-si-discipline/departamentul-de-stiinte-farmaceutice-de-specialitate-dsfs/chimie-farmaceutica/colectivul-disciplinei.html>), Department of Pharmaceutical Chemistry,
Faculty of Pharmacy, University of Medicine and Pharmacy Târgu Mures (<http://www.umftgm.ro/facultatea-de-farmacie/departamente-si-discipline/departamentul-de-stiinte-farmaceutice-de-specialitate-dsfs/chimie-farmaceutica/colectivul-disciplinei.html>)
Gh. Marinescu 38, 540139 Târgu Mures, Romania
Tel: 0040-265-215551
E-mail: gabriel.hancu@umftgm.ro (<https://apb.tbzmed.ac.ir/page/gabriel.hancu@umftgm.ro>)
Google scholar (<http://scholar.google.com/citations?user=eRfui44AAAAJ&hl=en>)



Khaled Nabih Zaki Rashed, PhD

National Research Centre (NRC),
Pharmacognosy Department,
Pharmaceutical and Drug Industries Research Division,
Dokki, Giza, Egypt
E-mail: khalednabih2015@yahoo.co.uk (mailto:khalednabih2015@yahoo.co.uk), khaledrashed_352@ymail.com (mailto:khaledrashed_352@ymail.com)
Google scholar (<http://scholar.google.com/citations?user=oFPg8YAAAAJ&hl=en>)




Kasturi Pawar, PhD

R&D Manager, Bausch Health Inc
Rohnert Park, California, USA
Email: kasturi.pawar@bauschheath.com (mailto:kasturi.pawar@bauschheath.com).
linkedIn (<https://www.linkedin.com/in/kasturi-p-34614314>)

| |
|--|
| Submit Your Paper (/Login) |
| Instructions for Authors (/InstructionsforAuthors) |
| Aims and Scope (/AimsandScope) |
| Editorial Board (/EditorialBoard) |
| Editorial Policies (/EditorialPolicies) |
| Publication Ethics (/Ethics) |
| About APB & Contacts (/ContactsandEditorialOffice) |
| Articles ahead of print (/Inpress) |
| Archive (/Archive) |

Journal Info:
Freq.: Quarterly
eISSN: 2251-7308 (https://road.issn.org/issn_search?afs:query=2251-7308#.Vw7aFpwwiUk)
pISSN: 2228-5881 (https://road.issn.org/issn_search?afs:query=2228-5881#.Vw7aFpwwiUk)
Permission (<https://creativecommons.org/licenses/>): CC BY



Platinum Open Access
(no submission or publication fees)
Powered by



Abstracting and Indexing

PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/journals/2246/>), Pubmed (<https://pubmed.ncbi.nlm.nih.gov/?term=%22Adv%20Pharm%20Bull%22%5BJournal%5D>),

Emerging Sources Citation Index (<http://mjl.clarivate.com/cgi-bin/jrnlst/jlresults.cgi?PC=MASTER&ISSN=2228-5881>)

Scopus (<https://www.scopus.com/sourceid/21100232413?origin=sbrowse>), Google Scholar (<https://scholar.google.com/citations?user=WWDfCCgAAAAJ&hl=enhttps://scholar.google.com/citations?user=WWDfCCgAAAAJ&hl=en>),

EMBASE/Excerpta Medica (<https://www.elsevier.com/solutions/embase-biomedical-research/embase-coverage-and-content>)

EBSCOhost (<https://www.ebscohost.com/titleLists/a9h-journals.htm>); CAS (https://cassi.cas.org/publication.jsp?P=LglBQf5Q2NQyz133K_lI3zLPXfcr-WXf_a0s1c_1-2Y3O7R7eJ0GCdLPXfcr-WXfimsBlkq8XcUjhmk0WtYxmzLPXfcr-WXfSHEqVQVf5dZsXLBusJR_0w); DOAJ (https://doaj.org/toc/2251-7308?source=%7B%22query%22%3A%7B%22filtered%22%3A%7B%22filter%22%3A%7B%22bool%22%3A%7B%22must%22%3A%5B%7B%22terms%22%3A%7B%22index.issn.exact%22%3A%5B%222228-5881%22%2C%2222251-7308%22%5D%7D%7D%2C%7B%22term%22%3A%7B%22_type%22%3A%22article%22%7D%7D%5D%7D%7D%2C%22query%22%3A%7B%22match_all%22%3A%7B%7D%7D%7D%2C%22size%22%3A100%2C%22_source%22%3A%7E)

source=%7B%22query%22%3A%7B%22filtered%22%3A%7B%22filter%22%3A%7B%22bool%22%3A%7B%22must%22%3A%5B%7B%22terms%22%3A%7B%22index.issn.exact%22%3A%5B%222228-5881%22%2C%2222251-7308%22%5D%7D%7D%2C%7B%22term%22%3A%7B%22_type%22%3A%22article%22%7D%7D%5D%7D%7D%2C%22query%22%3A%7B%22match_all%22%3A%7B%7D%7D%7D%2C%22size%22%3A100%2C%22_source%22%3A%7E

Advanced Pharmaceutical Bulletin

Q1 Pharmacology, Toxicology and Pharmaceutics... best quartile

SJR 2019 0.57

powered by scimagojr.com

(<https://www.scimagojr.com/journalsearch.php?q=21100232413&tip=sid&exact=no>)



Enter a search term

Title

ISSN: 2228-5881
<https://portal.issn.org/resource/ISSN/2228-5881> eISSN: 2251-7308
<https://portal.issn.org/resource/ISSN/2251-7308>

Clarivate
Web of Science™
 ISI Impact factor (2024): 4.1
 5 Year IF: 4.8


<https://www.webofscience.com/wos/woscc/basic-search>



ELSEVIER Advanced
Pharmaceutical Bulletin
 SCOPUS
 Cite score (2025):
 SNIP: 0
 SJR: 0.11

<https://www.scopus.com/sourceid/211002324132?origin=sbrowse>

- [Submit Your Paper \(/Login\)](#)
- [Instructions for Authors \(/InstructionsforAuthors\)](#)
- [Aims and Scope \(/AimsandScope\)](#)
- [Editorial Board \(/EditorialBoard\)](#)
- [Editorial Policies \(/EditorialPolicies\)](#)
- [Publication Ethics \(/Ethics\)](#)
- [About APB & Contacts \(/ContactsandEditorialOffice\)](#)
- [Indexing and Abstracting \(/IndexingAbstracting\)](#)



2026, Vol 16, No. 1

Advanced Pharmaceutical Bulletin (APB) is a peer-reviewed multidisciplinary open access journal, covering a wide range of integrative fields within Pharmaceutical sciences. APB is the official journal of Drug Applied Research Center and Faculty of Pharmacy, published by TUOMS PRESS (<https://publications.tbzmed.ac.ir/>), **Tabriz University of Medical Sciences** (<https://en.tbzmed.ac.ir/>).

Why Publish with APB?

- Free of charge publication for all article types
- Fast and constructive peer review
- Simple and efficient online submission
- Author-friendly review process
- Rapid publication by means of running issue concept, which gives authors the benefit of 'No Waiting Time' for the officially accepted manuscripts
- Free publication of color images
- Worldwide visibility of papers (Open Access Journal)

- [Articles In Press \(/Inpress\)](#)
- [Archive \(/Archive\)](#)

- [Current Issue \(/Current\)](#)
- [In Press \(/InPress\)](#)
- [Most Viewed \(/MostViewed\)](#)
- [Most Downloaded \(/MostDownloaded\)](#)
- [Most Cited \(/MostCited\)](#)

Journal Info:
 Freq.: Quarterly
 eISSN: 2251-7308
https://road.issn.org/issn_search?afs:query=2251-7308#.Vw7aFpwwiUK
 pISSN: 2228-5881
https://road.issn.org/issn_search?afs:query=2228-5881#.Vw7aFpwwiUK
 Permission
<https://creativecommons.org/licenses/>



Platinum Open Access



(no submission or publication fees)

Powered by



Abstracting and Indexing

Letter to Editor

Quercetin as a Candidate Adjunct for Calcineurin Inhibitor-Induced Adverse Effects in Transplant Patients

</Article/apb-46462>

Zahra Nazari Taloki* (<https://orcid.org/0000-0002-7919-9192>)

Adv Pharm Bull. 2026;16(1): 1-2. doi: 10.34172/apb.025.46462 (<https://doi.org/10.34172/apb.025.46462>)

- [Article \(/Article/apb-46462\)](/Article/apb-46462)
- [PDF \(/PDF/apb-16-1.pdf\)](/PDF/apb-16-1.pdf)
- [XML \(/XMLs/apb-46462\)](/XMLs/apb-46462)
- Cited By:

Letter to Editor

Association of Circular RNAs (circRNAs) in Hepatitis B Virus (HBV) Induced Hepatocellular Carcinoma (HCC): Emerging Diagnostic Biomarkers and Novel Therapeutic Targets

</Article/apb-46424>

Nalira Yaugoob (<https://orcid.org/0009-0002-1351-2489>), Kannan Subbaram* (<https://orcid.org/0000-0001-8547-0957>), Razana Faiz (<https://orcid.org/0000-0002-9841-4337>), Sheeza Ali (<https://orcid.org/0000-0002-0248-6628>), Queen Alice Arul (<https://orcid.org/0000-0002-4314-2311>)

Adv Pharm Bull. 2026;16(1): 3-5. doi: 10.34172/apb.025.46424 (<https://doi.org/10.34172/apb.025.46424>)

- [Article \(/Article/apb-46424\)](/Article/apb-46424)
- [PDF \(/PDF/apb-16-3.pdf\)](/PDF/apb-16-3.pdf)
- [XML \(/XMLs/apb-46424\)](/XMLs/apb-46424)
- Cited By:

Letter to Editor

Immunogenicity as a Key Challenge in Tissue Engineering: Toward Clinical Translation

</Article/apb-46533>

Arash Abdolmaleki* (<https://orcid.org/0000-0002-7454-8728>), Sina Jafari Dargahlou, Hussein A. Ghanimi

Adv Pharm Bull. 2026;16(1): 6-7. doi: 10.34172/apb.46533 (<https://doi.org/10.34172/apb.46533>)

- [Article \(/Article/apb-46533\)](/Article/apb-46533)
- [PDF \(/PDF/apb-16-6.pdf\)](/PDF/apb-16-6.pdf)
- [XML \(/XMLs/apb-46533\)](/XMLs/apb-46533)
- Cited By:

Original Article

Optimizing Expression of a Llama-Based Anti-PSMA Nanobody in *Escherichia Coli* and Its Application in Immunohistochemistry of Prostate Cancer Tissues

(/Article/apb-45447)

Seyedeh Sheila Seyed-Motahari  (<https://orcid.org/0009-0009-5723-2789>), Shahriyar Abdoli, Mohammad Ali Shokrgozar, Shiva Irani, Zahra Sharifzadeh*  (<https://orcid.org/0000-0002-4419-0315>)

Adv Pharm Bull. 2026;16(1): 62-73. doi: 10.34172/apb.025.45447 (<https://doi.org/10.34172/apb.025.45447>)

 Article

(/Article/apb-45447)

 PDF

(/PDF/apb-16-62.pdf)

 Suppl 1

(/Suppl/apb-16-62-s001.pdf)

 XML



(/XMLs/apb-45447)

Cited By:

Original Article

Apigenin as a Multi-Targeted Agent in Gastrointestinal Cancers: A Systems Pharmacology Approach

(/Article/apb-45970)

Duaa Kamel Al-Moussawi, Aseel Kamil Mohammed Al-Mosawi, Awatif Mokar Dayesh, Mohammad Hosseinzadeh Hesani*  (<https://orcid.org/0000-0002-9910-9385>), Hamid Cheshomi*  (<https://orcid.org/0000-0001-7925-7797>)

Adv Pharm Bull. 2026;16(1): 74-90. doi: 10.34172/apb.025.45970 (<https://doi.org/10.34172/apb.025.45970>)

 Article

(/Article/apb-45970)

 PDF

(/PDF/apb-16-74.pdf)

 Suppl 1

(/Suppl/apb-16-74-s001.pdf)

 XML


(/XMLs/apb-45970)

Cited By:

Original Article

The RNA-Binding Proteins Promote Resistance of Microglial Cells to Hypoxia

(/Article/apb-46054)

Mohammad Khosravi*  (<https://orcid.org/0000-0001-9510-3464>), Zohreh Ghotbeddin, Sorour Chinipardaz

Adv Pharm Bull. 2026;16(1): 91-109. doi: 10.34172/apb.025.46054 (<https://doi.org/10.34172/apb.025.46054>)

 Article

(/Article/apb-46054)

 PDF

(/PDF/apb-16-91.pdf)

 Suppl 1

(/Suppl/apb-16-91-s001.pdf)

 XML








(/XMLs/apb-46054)

Cited By:

Original Article

The Effect of Glycosylation on Biodistribution and Cytotoxicity of ^{99m}Tc-Radiolabeled Luteolin

(/Article/apb-46124)

Mostafa Pirali Hamedani  (<https://orcid.org/0000-0002-5748-825X>), Mohammad Seyedhamzeh  (<https://orcid.org/0000-0003-1632-4387>), Mohammad H. Ghahremani  (<https://orcid.org/0000-0001-5051-6214>), Abbas Hadjiakhoondi  (<https://orcid.org/0000-0001-9172-3543>), Morteza Pirali Hamedani  (<https://orcid.org/0000-0002-3474-2446>), Mehdi Shafiee Ardestani  (<https://orcid.org/0000-0002-0097-9779>), Zahra Tofighi*  (<https://orcid.org/0000-0001-8909-6595>)

Adv Pharm Bull. 2026;16(1): 110-118. doi: 10.34172/apb.025.46124 (<https://doi.org/10.34172/apb.025.46124>)

 Article

(/Article/apb-46124)

 PDF

(/PDF/apb-16-110.pdf)

 XML



(/XMLs/apb-46124)

Cited By:




Original Article

Psoralen and Seselin Stabilize the α -helix Structure in Lysozyme and Inhibit the α -helix to β -sheet Exchange: An Efficient Anti-Amyloidogenic Mechanism

(/Article/apb-40838)

Parisa Panah-Amand  (<https://orcid.org/0000-0001-5690-6213>), Leila Sadeghi*  (<https://orcid.org/0000-0003-1829-4388>), Arezu Marefat, Gholamreza Dehghan





Adv Pharm Bull. 2026;16(1): 119-128. doi: 10.34172/apb.025.40838 (<https://doi.org/10.34172/apb.025.40838>)

 Article
(/Article/apb-40838)
 PDF
(/PDF/apb-16-119.pdf)
 XML
(/XMLs/apb-40838)
Cited By:




Original Article

GAS2 Co-Expression Networks in Breast Cancer: Identification of Potential Biomarkers and Therapeutic Targets

(/Article/apb-46055)

Samin Rahimi  (<https://orcid.org/0000-0002-3081-6583>), Mehdi Haghi*  (<https://orcid.org/0000-0001-8400-4209>), Dariush Najarzadeh  (<https://orcid.org/0000-0003-4214-3969>), Mohammad Ali Hosseinpour Feizi  (<https://orcid.org/0000-0002-1508-5022>)




Adv Pharm Bull. 2026;16(1): 129-138. doi: 10.34172/apb.025.46055 (<https://doi.org/10.34172/apb.025.46055>)

 Article
(/Article/apb-46055)
 PDF
(/PDF/apb-16-129.pdf)
 XML
(/XMLs/apb-46055)
Cited By:




Original Article

Eplerenone Attenuates Hepatic Oxidative Stress and Mitochondrial Dysfunction Following Renal Ischemia-Reperfusion Injury in Rats

(/Article/apb-45926)

Alireza Barati  (<https://orcid.org/0000-0003-2922-2101>), Seyed Mohammadmahdi Meybodi, Kimia Moradi, Sana Nouraei, Mohammad Bakhshi, Soheila Montazersaheb*  (<https://orcid.org/0000-0001-5010-7293>), Sepideh Zununi Vahed*  (<https://orcid.org/0000-0003-0179-4562>)



Adv Pharm Bull. 2026;16(1): 139-148. doi: 10.34172/apb.025.45926 (<https://doi.org/10.34172/apb.025.45926>)

 Article
(/Article/apb-45926)
 PDF
(/PDF/apb-16-139.pdf)
 XML
(/XMLs/apb-45926)
Cited By:




Original Article

Hidden Hazards: Blood Lead and Cadmium Levels Associated with Biochemical and Hematological Markers

(/Article/apb-46563)

Mina Islambulchilar*  (<https://orcid.org/0000-0001-8355-8795>), Ali Shayanfar  (<https://orcid.org/0000-0001-7507-9057>), Meisam Bagheri, Omid Mehri


Adv Pharm Bull. 2026;16(1): 149-156. doi: 10.34172/apb.025.46563 (<https://doi.org/10.34172/apb.025.46563>)

 Article
(/Article/apb-46563)
 PDF
(/PDF/apb-16-149.pdf)
 XML
(/XMLs/apb-46563)
Cited By:




Original Article

Histone Deacetylase Inhibitor Combined with Rosiglitazone Improves Cognitive Function Via Microglial Polarization and Increased Mature/Pro-BDNF in Alzheimer's Disease

(/Article/apb-46129)

Melina Rafiey  (<https://orcid.org/0000-0003-0379-4371>), Rahim Nosrati, Arash Pourgholaminejad, Saba Ahangaran, Parvin Babaei*  (<https://orcid.org/0000-0003-4870-8182>)


Adv Pharm Bull. 2026;16(1): 157-165. doi: 10.34172/apb.025.46129 (<https://doi.org/10.34172/apb.025.46129>)

 Article
(/Article/apb-46129)
 PDF
(/PDF/apb-16-157.pdf)
 XML
(/XMLs/apb-46129)
Cited By:




Original Article

Dual Modulation of Senescence and Immune Checkpoints by Metformin and Dapagliflozin Attenuates Liver Fibrosis in a Thioacetamide-Induced Rat Model

(/Article/apb-46231)

Asmaa Ramadan, Ahmed A. Shaaban, Mohammad E. Rabeh, Ahmad M. Rabi, Eslam E. Abd El-Fattah, Amal K. Seleem, Ibrahim Osman, Ayman Salama, Noha M. Gamil, Ahmed S.G. Srag El-Din*  (<https://orcid.org/0000-0002-9924-3154>)



Adv Pharm Bull. 2026;16(1): 166-178. doi: 10.34172/apb.025.46231 (<https://doi.org/10.34172/apb.025.46231>)

 Article
(/Article/apb-46231)
 PDF
(/PDF/apb-16-166.pdf)
 XML
(/XMLs/apb-46231)
Cited By:




Original Article

Galangin's Therapeutic Potential in Retinoblastoma: Inducing Apoptosis and Modulating RB Protein and Some MicroRNAs

(/Article/apb-46369)

Maryam Zamani Sani  (<https://orcid.org/0009-0006-2527-6259>), Mohammad Mirzaei, Ali Mota, Effat Alizadeh, Maryam Ghasemi, Elmira Aboutalebi Vand Beilankouhi, Niloufar Kheradi, Mohammad Rahmati*  (<https://orcid.org/0000-0001-7791-3287>)




Adv Pharm Bull. 2026;16(1): 179-188. doi: 10.34172/apb.025.46369 (<https://doi.org/10.34172/apb.025.46369>)

 Article
(/Article/apb-46369)
 PDF
(/PDF/apb-16-179.pdf)
 XML
(/XMLs/apb-46369)
Cited By:




Original Article

The Effects of Coenzyme Q10 Supplementation on the Contrast Sensitivity Score, Biomarkers of Oxidative Stress, Inflammation, and β -Secretase Activity in the Blood and the Correlation Among these Factors in Diabetic Retinopathy Patients; Clinical Trial

(/Article/apb-46420)

Mohammad Hossein Sharif  (<https://orcid.org/0000-0002-2172-3043>), Fatemeh Javadian Sarraf, Ehsan Sharifipour, Masumeh Zamanlu  (<https://orcid.org/0000-0002-6326-8448>), Parsa Gholipour, Alireza Soltanian, Siamak Shahidi, Abdolrahman Sarihi*  (<https://orcid.org/0000-0002-2452-5210>)

Adv Pharm Bull. 2026;16(1): 189-205. doi: 10.34172/apb.46420 (<https://doi.org/10.34172/apb.46420>)

 Article
(/Article/apb-46420)
 PDF
(/PDF/apb-16-189.pdf)
 XML
(/XMLs/apb-46420)
Cited By:

Original Article



Biomimetic Scaffold of Chitosan from *Litopenaeus vannamei* Shrimp Shells Incorporated with Collagen and Hydroxyapatite for Bone Tissue Regeneration

Cheryn Ivana¹, Hendrik Satria Dwi Putra, Nyoman Bayu Wisnu Kencana, Agustina Setiawati¹

Department of Pharmaceutical Biology, Faculty of Pharmacy, Sanata Dharma University, Yogyakarta, Indonesia

Article info

Article History:

Received: June 4, 2025

Revised: September 19, 2025

Accepted: December 17, 2025

ePublished: December 21, 2025

Keywords:

Polymer, Shrimp shells,
Litopenaeus vannamei,
Bone graft, Tissue regeneration

Abstract

Introduction: The goal of this study was to create a biocompatible bone tissue engineering scaffold from *Litopenaeus vannamei* shrimp shell chitosan with hydroxyapatite (HAP) and collagen type I (COL I), and to investigate its physicochemical and biological properties relative to commercial chitosan scaffolds.

Methods: The chitosan was extracted by following steps: deproteination, demineralization, and deacetylation processes, further characterizing it through composite FTIR spectroscopy. The scaffolds were fabricated using lyophilization, followed by the evaluation of their morphology, porosity, swelling ratio, degradation rate, and compressive strength. The scaffold morphology and porosity were observed using Scanning Electron Microscopy (SEM) and the solvent displacement method. Swelling and degradation ratio were investigated in phosphate buffer saline, while compressive strength was investigated with the Universal Testing Method. For the assessment of cytocompatibility, MG-63 osteoblast-like cells were subjected to the MTT assay, and cell morphology on the scaffold was observed under SEM.

Results: As shown in the FTIR results, the derived chitosan exhibited comparable functional groups to those of commercial chitosan, confirming its successful extraction. Both scaffolds exhibited interconnected pores and suitable diameters and porosity for bone scaffold tissue engineering. Chitosan from shrimp shells showed a reduction in swelling ($278.55 \pm 36.49\%$ at 24h) and a slower degradation rate ($41.87 \pm 7.27\%$ at 4 weeks) compared to commercial scaffolds, possibly due to higher residual minerals and a lower degree of deacetylation. However, compressive strength 0.991 ± 0.01 MPa and attachment and proliferation of MG-63 cells were similar, suggesting good osteoconductivity of the biomaterials.

Conclusion: Chitosan-derived shrimp shells are a sustainable biomaterial candidate for bone tissue engineering. The scaffold based on shrimp shells exhibited relatively lower degradation and moderate swelling, adequate mechanical stability, and bioactivity to support osteoblast-like cell adhesion and viability, suggesting it is adequate for bone tissue engineering applications.

Introduction

Bone is a complex connective tissue that provides mechanical support, blood production, and organ protection, which is remarkably dynamic, continuously self-regenerates, and repairs after damage.¹ For instance, in the case of tiny bone fractures, simple immobilization allows spontaneous healing over time. Defects caused by fracture, trauma, tumor excision, spinal deformity, and infection may surpass the critical size threshold and fail to heal natural physiological mechanism, thereby necessitating the use of supplementary materials to bridge the gap.²⁻³ The healing of bone defects has progressed through medical guidelines for bone grafting, including autografts and allografts, which are high-cost and high-infection-risk.⁴⁻⁵ Bone tissue engineering (BTE) is a potential alternative for autografts and

allografts, employing synthetic grafts to promote tissue regeneration. An artificial graft, a scaffold, should serve as a filler within the defect site and encourage bone regrowth.¹ To facilitate bone regeneration, a scaffold should be osteoconductive, enabling bone growth on its surface, while also providing a highly porous framework.^{6,7} In addition to these characteristics, a scaffold should have sufficient mechanical strength to sustain bone ingrowth at the implantation site, preserve structural integrity throughout *in vivo* tissue remodeling, and degrade over time in tandem with bone regeneration.^{9,8}

Both natural and synthetic polymers have been widely explored for scaffold fabrication.⁹ Among them, chitosan, a deacetylated form of chitin, is the primary structural biopolymer in crustacean exoskeletons such as shrimps,

*Corresponding Author: Agustina Setiawati, Email: nina@usd.ac.id

© 2026 The Author (s). This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.

lobsters, and crabs.¹⁰ It has gained particular attention and featured a linear structure consisting of $\beta(1-4)$ glycosidic bonds connecting d-glucosamine residues, interspersed with varying numbers of randomly distributed N-acetyl-d-glucosamine (NAG) units.¹ It serves as a good substrate for cell adhesion and proliferation to secrete extracellular matrix (ECM), which mimics the natural structural protein of bone ECM. Thus, it serves to deliver growth factors to improve bone regeneration by providing a biomimetic microenvironment for bone regeneration.¹¹ Due to its biodegradability, biocompatibility, antibacterial effect, and porous structure-forming ability, chitosan is considered a highly versatile biomaterial for tissue engineering.^{6,12,13} Our previous studies successfully engineered chitosan from mangrove and blue swimming crab to be a biomimetic composite for bone tissue engineering.^{14,15}

Thus, this study uses collagen, chitosan from shrimp (*Litopenaeus vannamei*) as a sustainable resource, aligning with United Nations Sustainable Development Goals (SDGs) by following deproteination, demineralization, and deacetylation steps.^{16,17} The shrimp shells contained more chitosan with a higher degree of deacetylation than that extracted from blue swimming crab and mangrove shells in our previous study.^{13,14,17,18} Since the human bone consists of a majority of collagen I (COL I) and hydroxyapatite (HAP), this study combined shrimp shells-derived chitosan into a scaffold to improve biocompatibility with tissue and impede toxicity effects. Moreover, COL I owes arginine-glycine-aspartic acid (RGD) peptides, which are a domain for $\alpha 1\beta 1$ and $\alpha 2\beta 1$ integrin receptors of the cells.^{19,20} The application of tissue-specific ECM components is an excellent strategy to grow specific cells²¹ in bone tissue engineering. COL I on the scaffold provides a chemical biomimetic component since it is the major ECM component on human bone,²²⁻²³; however, the composition needs further development by combining with HAP, which structurally supports bone, leading to ectopic bone formation.²⁴⁻²⁵ HAP is an apatite mineral that occurs naturally. It makes up 70% of bone; therefore, it stimulates osteoblast proliferation independent of the extracellular matrix and facilitates osteointegration. HAP not only improves the scaffold strength and osteoconductivity, but also prevents the scaffold from defects.^{26,27,28} Previous studies have also highlighted the synergistic effects of combining chitosan with COL I and HAP for bone tissue engineering. Chitosan, COL I, and HAP scaffolds have been shown to enhance cellular adhesion and proliferation, as well as promote osteoblast and stem cell differentiation.^{27,29,30} The combination of COL I and HAP significantly upregulated osteogenic markers compared to chitosan alone.³¹ Our results highlight the potential of shrimp shell-derived chitosan enriched with COL I and HAP as an innovative biomaterial for bone tissue regeneration.

In this study, the main goal is to develop sustainable bone tissue engineering based on chitosan isolated from shrimp (*Litopenaeus vannamei*) shells. The extracted chitosan was characterized structurally and chemically, then combined

with HAP and COL I into a three-dimensional scaffold that structurally and compositionally mimics the natural bone. The composite scaffold was engineered through simple lyophilization without using a crosslinker. Despite having discovered that other researchers have also investigated chitosan-based composite scaffolds for bone tissue engineering, their exceptional performance and the use of shrimp shells as a chitosan source and a straightforward production process, absent of cross-linking, have never been published.

Materials and Methods

Materials

Litopenaeus vannamei was collected from a local market in Yogyakarta in January 2023 and was authenticated in the Laboratory of Animal Systematics, Faculty of Biology, Universitas Gadjah Mada (N.46/BI/SH/III/2023). Sigma-Aldrich supplied commercial chitosan (419419), Pluronic F127 (P2443), bovine skin collagen (C4243), and paraformaldehyde (15817). Gibco also provided phosphate-buffered saline (10010-023). Phosphoric acid was supplied by Merck (1.000573.1000). The number of living cells was measured with Invitrogen's 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (M6494). For extraction, sodium hydroxide (NaOH) (1310-73-2) was purchased from Topaz Chemical, and hydrochloric acid was purchased from Smart Lab (100317). MG63 cells were propagated in high glucose medium Dulbecco's Modified Eagle's Medium (DMEM, Gibco) containing 10% Fetal Bovine Serum (FBS, Gibco 16000044) and 1% penicillin-streptomycin (Gibco, 10378016). All the well plates, pipettes, and tips used in this work were obtained from SPL Life Science, Corning, and Biologix.

Chitosan Extraction and Characterization

The shells were removed, sorted, and cleaned using flowing water. The shrimp shells were dried in the oven, powdered, and stored in an air-tight container until used. The chitosan extraction from shrimp shells was conducted according to our previous studies with deproteination, demineralization, and deacetylation.^{13,14} The isolated chitosan was then confirmed by FTIR spectroscopy to detect its functional group compared to the commercially available chitosan.

Determination of Degree of Deacetylation (DD) of Extracted Chitosan

This study estimated the degree of deacetylation (DD) of shrimp shell chitosan and commercial chitosan using FTIR spectroscopy, specifically based on the absorption bands observed at 1320 and 1420 cm^{-1} .³² The band at 1320 cm^{-1} is attributed to the acetylated amine or amide functionality, whereas the band at 1420 cm^{-1} has been validated in previous studies as a reliable reference for DD determination, in agreement with ¹H NMR and ¹³C NMR studies reported by Czechowska-Biskup et al.³³ The DD values were subsequently calculated based on a previous

study using the subsequent equation³²:

$$DD\% = 100 - \left(\frac{A_{1320}}{A_{1420}} - 0.3822 \right) * \frac{1}{0.03133}$$

Scaffold Fabrication

To prepare the composite, hydroxyapatite (1.75 g) was first dissolved in 2% phosphoric acid and stirred by a magnetic stirrer. Chitosan (0.5 g), dissolved in 10 mL of acetic acid, was then incorporated into the hydroxyapatite solution to form a mixture. The composite was then mixed with bovine collagen (0.25 g) solution in acetic acid (10 mL). The scaffold solution was then neutralized to pH 7 with sodium hydroxide and adjusted with demineralized water until it contained HAP, chitosan, and collagen at final concentrations of 175, 50, and 25 µg/mL, precisely. The prepared solution was cast into a silicon mold and frozen at -80 °C for 24 hours to preserve its structure, followed by lyophilization for 24 hours to remove residual solvents and obtain a porous composite. A control scaffold was also engineered using medium-molecular-weight chitosan that was bought commercially, applying the same methods and materials as the chitosan that was isolated from the shrimp shells.

Scaffold Morphology and Pore Diameter

Scaffold morphology was examined by SEM (JEOL JSM7100F) after sectioning, mounting on an aluminum stub with carbon tape. The sample images were taken at 50x and 250x magnification. Thus, pore size was analyzed using ImageJ at five replications. Energy-dispersive X-ray spectroscopy (EDS) was used on the same equipment for elemental analysis.

Porosity

Dry composites were first weighed (W_0), then fully submerged in 100% ethanol. After removal, residual ethanol on the outer layer was gently blotted, and the composites were weighed again (W_1). Each group was tested in five replicates were evaluated to calculate means and standard deviations.³⁴

$$Porosity (\%) = \frac{W_1 - W_0}{\rho \times V} \times 100\%$$

Swelling Ratio

The scaffolds were initially submerged in PBS at 37°C (W_0) and incubated for 1, 3, 6, 12, and 24 hours. After each time point, traces of PBS on the scaffold surface were thoroughly blotted before analysis before being analyzed.^{34,35}

$$Swelling \text{ ratio } (\%) = \frac{W_1 - W_0}{W_0} \times 100\%$$

Degradation Ratio

The dry samples (W_0) were initially soaked in PBS at 37°C PBS solution for 1, 2, 3, and 4 weeks. After incubation, the samples were removed and dried in an oven (W_1).²⁸ The degradation ratio was derived utilizing the

following equation:

$$Degradation \text{ ratio } (\%) = \frac{W_1 - W_0}{W_0} \times 100\%$$

Compression Strength

A RT1-1225 A&D Company Universal Testing Machine (UTM) was used to evaluate the composites' compression strength.³³ The composites had rectangular shapes with a length-to-diameter ratio of 2:1 and were compressed with a pressure of 2.5 kN, as previously studied by Wang et al³⁰ and Zhao et al.³⁶

$$Compressive \text{ strength } (MPa) = \frac{F_c}{A}$$

Scaffold Bio Functionality Test

MG-63 cells (5×10^5) were propagated on a composite in a 24-well plate, which was previously coated with 5% Pluronic-127 for 30 minutes. After 6 h of adhesion, composites were replaced with new media on a new 24-well plate and cultured for 96 hours. Tetrazolium salt solution was added to the well to quantify cell viability, and the cells were cultured for an hour at 37 °C. The absorbance was determined at 450 nm with a Perkin Elmer multi-plate reader. For microscopy, samples were first fixed with 4% paraformaldehyde and then dehydrated in graded ethanol (70-100%).

Results and Discussion

The fabrication process of chitosan-based scaffolds is described in Figure 1. Shrimp shell-derived chitosan was combined with micro-fine HAP and COL I to engineer bio bio-composite scaffold, then the bio-functionality of the scaffold was assayed by seeding osteoblast-like cells (MG-63) into the scaffold. Such scaffolds are designed to support osteoblast growth *in vitro* and, in future applications, may be transferred to bone defects to facilitate regeneration.

Chitosan extraction from Shrimp (*Litopenaeus vannamei*) shells

This study extracted chitosan from shrimp (*Litopenaeus vannamei*) shells in three stages: deproteinization, demineralization, and deacetylation (Figure 2a). Crustacean shells are primarily composed of calcium and magnesium carbonate (20- 50%), protein (20- 40%), chitin (15-40%), with minor constituents including lipid, astaxanthin, and other minerals.^{37,38} Proteins are removed from shells using 5% sodium hydroxide at 80°C for 4 hours. The weight lost during deproteinization was considered as protein as much as 57.04 ± 8.73 %. During the demineralization step, the residual shell is exposed to 5 % hydrochloric acid, which removes the minerals through reactions with CaCO_3 and $\text{Ca}_3(\text{PO}_4)_2$. The powder obtained from this stage is chitin, which displays limited dissolvability and chemical activity because of its stiff structure and numerous hydrogen bonds. The powder obtained from this step is chitin, which is turned to chitosan by cleaving the acetamide group with concentrated sodium hydroxide, resulting in acetate ions and an $-\text{NH}_2$ group that renders the chitosan acid-soluble.^{38,39} The chitosan




Figure 1. Scheme of Chitosan-based Scaffold from *Litopenaeus vannamei* Shell Waste for Bone Tissue Engineering. HAP: hydroxyapatite. This figure created using BioRender.




Figure 2. Chitosan extraction from *Litopenaeus vannamei* Shells. a. Steps of chitosan extraction and the results, b. Fourier Transform Infrared Spectroscopy (FTIR) spectroscopy analysis of extracted chitosan. RT: room temperature, NaOH: sodium hydroxide, and HCl: chloride acid

extracted from shrimp shells was $22.37 \pm 1.25\%$, appearing as an off-white powder. It is similar to previous studies by Ngerngyung and colleagues⁴⁰ but less white than the chitosan isolated from crab shells from our previous study. It is explained by the presence of higher astaxanthin in shrimp shells than crab shells, resulting in a more intense color of chitosan powder.⁴¹ Since the chitosan property is determined by the degree of deacetylation (DD), the DD determination was important to calculate DD before scaffold fabrication. The DD of shrimp shell chitosan was 77.22% while the commercially available chitosan was 69.87%, calculated based on Fatima.³² This result was consistent with previous studies in which *Litopenaeus vannamei* shell-derived chitosan has a DD value of about 80%.⁴⁰⁻⁴² In the deacetylation step, the acetyl groups are removed from chitin molecules by a high concentration of NaOH to form an amino group ($-\text{NH}_2$). The high degree of these amino groups is correlated with the reactivity of chitosan molecules.⁴³

To confirm the functional groups, FTIR spectra were used to compare extracted chitosan and commercially available chitosan as the standard, as revealed in Figure 2b. Both of the chitosan exhibited identical spectra, with a

peak at $3363\text{-}3293\text{ cm}^{-1}$ corresponding to the stretching vibrations of water and hydroxyls, and free amino groups (NH_2). The signal at 2875 cm^{-1} indicates an asymmetric stretching of CH_2 in chitosan. The remaining acetamido groups stretch their $-\text{C}-\text{O}$ bonds, resulting in amide frequencies of 1650 and 1557 cm^{-1} . At 1419 cm^{-1} , the spectrum exhibited $-\text{NH}_2$ deformation, whereas the band at 1376 cm^{-1} represents $\text{C}-\text{C}-\text{H}$ symmetric bending typical of alcohol groups. The $\text{C}-\text{N}$ stretching was detected at 1311 cm^{-1} , and the $-\text{CO}$ stretching of alcohol groups was observed at 1068 and 1029 cm^{-1} for the alcohol groups' vibration.⁴⁰ The peak of $\text{C}-\text{O}-\text{C}$ asymmetric stretching vibration appeared at 1150 cm^{-1} , representing glycosidic bands.⁴⁴ Polysaccharide fingerprints exhibit a distinct infrared spectrum in the $1000\text{-}920\text{ cm}^{-1}$ area due to variations in glycosidic link structure.⁴⁰ In the FTIR spectrum, $\text{C}-\text{C}$ and $\text{C}-\text{O}$ stretching vibrations were detected in Region II ($1200\text{-}800\text{ cm}^{-1}$), while Region V ($3600\text{-}3050\text{ cm}^{-1}$) corresponded to OH stretching vibrations and Region IV ($3050\text{-}2800\text{ cm}^{-1}$) to CH/CH_2 stretching vibrations.⁴⁵ Since the extracted chitosan has a band stretching pattern that matches the stretching band of commercial standard chitosan, it is confirmed that the

isolated biomaterial is indeed chitosan.

Furthermore, we engineered a scaffold using shrimp shell-derived chitosan incorporating COL I and HAP for osteoblast proliferation. The composite solution was then cast in a silicone mold and dried using the lyophilization method (Figure 3a). The engineered scaffold was an off-white and sponge-like 3D structure (Figure 3b). FTIR spectroscopy was employed to investigate the chemical composition of the composite scaffold. The broad band at $3500\text{--}3300\text{ cm}^{-1}$ represented N-H and O-H stretching vibration, which indicates intra- and intermolecular hydrogen bonds, typically associated with COL I, and chitosan structures.^{43,46} In addition, the presence of peaks at $1651, 1588$ and $1416\text{--}1250\text{ cm}^{-1}$ corresponded for C=O stretching, amide I, and C-N stretching vibration, confirming the characteristic functional groups of the scaffold component.^{16,43,44} N-H group bending is investigated to be responsible for a peak at 1537 cm^{-1} .⁴⁵ A recent study identified the absorption of the PO_4^{4-} group at $1095, 1031, 961, 603,$ and 563 cm^{-1} .¹⁸ Our study discovered a distinct and strong peak at 1029 cm^{-1} , which attributes to the PO_4^{3-} group (Figure 3c). Hence, the peak for the hydrogen phosphate group appeared at 875 cm^{-1} , and the carbonate groups appeared at 1407 cm^{-1} .⁴⁶

Hence, collagen I specific bands such as amide A ($3200\text{--}3300\text{ cm}^{-1}$), amide B ($2950\text{--}2919\text{ cm}^{-1}$) could not

be clearly observed due to overlapping bands with for N-H and O-H groups of chitosan.⁴⁷ Moreover, further analysis is needed to accurately determine the elements' composition of the scaffold using EDS. The presence of Ca and P was indicated by strong peaks for calcium and phosphate in the EDS spectra (Figure S1, Table S1). The shrimp shell scaffold was constructed of O (46.17%), Ca (21.68%), C (21.34%), and P (10.80%), which aligned with a previous study of Chi/Col I/HAP composite.²⁴ To sum up, the lyophilization method has successfully engineered a biomimetic scaffold for bone tissue regeneration.

Porosity and pore size are characteristics of the scaffold that are crucial for tissue regeneration. In tissue engineering, they are frequently tailored to meet the unique requirements of the desired tissue. Thus, we examined our scaffold microarchitecture under SEM. Both the shrimp shell and the commercial chitosan scaffold exhibited an open pore structure with irregular shape and an interconnected network (Figure 3d). The surface pore diameter of 78.38 ± 52.00 and $100.17 \pm 18.65\ \mu\text{m}$; while the inner pore diameter was 144.5 ± 27.57 and $107.56 \pm 32.3272\ \mu\text{m}$, respectively, for commercial and shrimp shell chitosan scaffold (Figure 3e). The wide range of pore diameter is caused by the irregular pore shape of the scaffold. Thus, the porosity of the scaffolds was $61.85 \pm 2.61\%$ and $64.71 \pm 0.77\%$ for commercial




Figure 3. Fabrication, macroscopic, and microscopic characteristics of shrimp and commercial chitosan-based scaffolds; a. Fabrication scheme of the scaffold, b. Macroscopic image of the fabricated scaffold, c. FTIR spectra of engineered and commercial chitosan-based scaffolds, d. Scanning Electron Microscopy (SEM) images of the scaffold's surface, e. Pore diameters of the surface and inner of engineered and commercial chitosan-based scaffolds ($n=5$), f. The porosity of engineered and commercial chitosan-based scaffolds

and shrimp shell chitosan scaffolds (Figure 3f). Porosity percentages vary from 30% to 90% or higher, depending on many variables such as the tissue type undergoing regeneration, the desired mechanical properties, and the method used in scaffold development. The porosity of bone tissue varies from 70% to 90% in spongy bone and 5% to 30% in compact bone. In tissue engineering, porosity is often tailored for each application to balance features like stiffness and cell infiltration; thus, scaffolds have no established or typical value.⁴⁸

A crucial factor for a scaffolding system in tissue engineering is water uptake. Controlling swelling behavior is similarly important to managing porosity when it involves maintaining the scaffolds' fidelity and integrity during interactions with biological fluids. This characteristic influences the transport of nutrients into the scaffold so that they support cell availability, proliferation, and differentiation. The scaffolds became swollen in PBS (pH 7.4) at 37 °C for 24 hours to determine the amount of water that the scaffold absorbed (Figure 4a and 4b). The swelling ratios of the commercial scaffolds were 900.97 ± 91.77 , 978.69 ± 60.38 , 1030.38 ± 67.86 , 818.56 ± 81.03 , and 931.76 ± 45.64 % at 1, 3-, 6-, 12-, and 24-hour incubation. While shrimp shells scaffolds had a swelling ratio of 204.79 ± 13.53 , 247.56 ± 16.94 , 262.64 ± 12.50 , 279.44 ± 28.02 , and 278.55 ± 36.49 % at the same duration of incubation.

Because chitosan and COL I are both hydrophilic materials, the designed scaffolds were demonstrated to have a significant swelling ability.⁴⁹ Chitosan in the scaffold composite with other polymers, such as polyvinyl alcohol (PVA), was reported to increase the swelling ratio.⁵⁰ The water uptake capacity of commercial chitosan scaffolds was drastically higher than shrimp shell chitosan scaffolds. It is considered that commercially available chitosan takes up take water than the shrimp shell chitosan. Since both scaffolds displayed no significant difference in porosity and pore diameter, the existence of impurities such as calcium carbonate and protein hinders the water uptake properties of the shrimp shell chitosan.⁵¹

In tissue engineering applications, biodegradability is a crucial characteristic for building scaffolds. Ideally, the scaffolds will break down through a regulated process and become integrated by the surrounding tissues without requiring surgical revision.⁵² In addition, lysozyme catalyzes the breakdown of chitosan over its β -1-4-glycosidic bonds.⁵³ The rate at which porous scaffolds degrade affects cell vitality, cell proliferation, and even host responses. The degradation ratio of the commercial chitosan scaffold was 22.53 ± 1.99 , 42.56 ± 5.26 , 46.43 ± 1.11 , and 47.37 ± 2.03 % at 1, 2, 3, and 4 weeks. While shrimp shells chitosan had degradation ratios of 4.74 ± 1.72 , 10.25 ± 2.67 , 21.15 ± 17.00 , and 41.87 ± 7.27 %, respectively. This reduced degradation could be attributed




Figure 4. Swelling, degradation, and compression strength characteristics of shrimp and commercial chitosan-based scaffolds; a. Swelling images of the scaffolds at 0, 4, and 24 hours; b. Swelling ratio of the scaffolds at 0, 1, 4, 6, 12, and 24 hours; c. Degradation images of the scaffold at 0, 2, and 4 weeks (n=5); d. The degradation ratio of the scaffolds 0-, 1-, 2-, and 4-week (n=5); e. Scheme of compression strength test; f. Compression strength of shrimp and commercial chitosan-based scaffolds (n=3)

to its lower purity of the isolated chitosan, which makes it slower to absorb water, thereby delaying degradation. Previous studies also reported that chitosan extracted from crustacean shells exhibited slower degradation rates due to its heterogeneous structure, residual minerals, lower accessibility to hydrolyzed enzyme and variable DD, compared to highly purified commercial chitosan.^{54,55}

Designing composite scaffolds for bone tissue engineering requires a thorough investigation of their mechanical properties. Bone strength and load-bearing capacity are the two major components of bone healing, depending on the scaffolds' mechanical strength. The mechanical strength of scaffolds is a crucial property for the integrity as well as proliferation of the osteoblast.⁵³ During compression testing works by putting the scaffold in a solid stage and pressed from above to evaluate its resistance to compression (Figure 4e). The shrimp shell scaffolds had a compressive strength of 0.991 ± 0.01 MPa, compared to 0.97 ± 0.01 MPa for the control scaffold (Figure 4e). All quantitative data were provided as SD for three samples. Although the scaffolds exhibited lower compressive strength than cortical bone (100- 230 MPa), their values fell within the range of cancellous bone (2- 12 MPa), suggesting suitability for trabecular bone applications. Even though their mechanical strength did not meet the criteria for bone tissue engineering, chitosan-based scaffolds seeded with osteoblast or stem cells had increased mechanical properties due to matrix mineralization.^{56,57}

An ideal tissue engineering scaffold ought to be attached by the cells and not trigger cell cytotoxicity, which is assessed using cell binding and *in vitro* MTT assays. The cell binding protocols were conducted based on our previous studies, which were slightly modified by seeding the cells on the scaffold in the Pluronic-coated well plate (Figure 5a).^{14,15} The viability of the cells was measured by tetrazolium salt absorbance at 450 nm. On 24, 48, 96, and 144 hours after cell seeding, the absorbance was 0.112 ± 0.01 , 0.237 ± 0.09 , 0.765 ± 0.201 , and 1.317 ± 0.254 , respectively (Figure 5b). The MG-63 cells' attachment and support were supported

by COL I in the fabricated scaffold, which was considered the main factor instead of the interconnected network of the chitosan scaffold.²³ Moreover, the cells' morphology on the scaffold was observed under SEM microscopy 4 days after seeding (Figure 5c). Microarchitecture of an open connected pore in the scaffold due to the interaction with the cells. The cells bind to the scaffold on the RGD peptide of collagen through the integrin receptor, then they secrete the ECM network surrounding the cells and remodel the interconnected networks of the scaffolds^{58,59} as Figure 5c. Thus, this interaction between cells and scaffolds happened reciprocally, giving biochemical cues for cell proliferation to be a specific tissue. Besides its microstructure, the chemical properties of the scaffold affect the behavior of cells to determine the cell's fate.⁶⁰

Taken together, this study developed a biomimetic scaffold for bone tissue engineering incorporating chitosan derived from the shrimp *Litopenaeus vannamei* shells with COL I and HAP. It gives an insight into the potential use of marine biowaste for the fabrication of biopolymers by comparing the physicochemical properties, degradation behavior, and biological performance of shrimp shell-derived chitosan scaffolds and commercial chitosan scaffolds. The detailed characterization and *in vitro* analysis of our engineered scaffolds will elucidate their prospects for bone regeneration, especially for the development of cost-efficient strategies and greener materials for use in biomedicine.

Conclusion

This study successfully engineered shrimp shell-derived chitosan to be a biomimetic scaffold that supported osteoblast viability. The extracted chitosan had a high DD and sufficient purity for scaffold engineering, and its chemical characteristics were similar to those of commercial chitosan. Chitosan and HAP's distinctive peaks were easily distinguished in FTIR spectra, although overlapping peaks covered up collagen-specific bands. Because of their higher purity, commercial chitosan scaffolds showed a higher swelling ratio and




Figure 5. Biocompatibility test of engineered scaffolds: a. Scheme of cell seeding on the scaffold, b. The absorbance of formazan complex at 450 nm after 24-, 48-, and 144-hours incubation (n=4), c. SEM image of MG-63 cells and the extracellular matrix fibers on the scaffold (yellow: MG-63 cells, green: ECM fibers). PBS: phosphate buffer saline.

degradation than the engineered scaffolds. In the range of cancellous bone, both scaffold types demonstrated comparable compressive strengths and promoted the adhesion and proliferation of MG-63 cells, demonstrating biocompatibility. These results demonstrate that chitosan made from marine biowaste has the potential to be an economical and environmentally friendly substitute for bone tissue engineering applications.

Author Contribution

Conceptualization: Agustina Setiawati.
 Data curation: Agustina Setiawati.
 Formal analysis: Agustina Setiawati, Cheryn Ivana, Nyoman Bayu Wisnu Kencana.
 Funding acquisition: Agustina Setiawati.
 Investigation: Agustina Setiawati.
 Methodology: Cheryn Ivana, Hendrik Satria Dwi Putra, Nyoman Bayu Wisnu Kencana.
 Project administration: Hendrik Satria Dwi Putra, Nyoman Bayu Wisnu Kencana.
 Resources: Agustina Setiawati.
 Software: Cheryn Ivana, Hendrik Satria Dwi Putra.
 Supervision: Agustina Setiawati.
 Validation: Agustina Setiawati.
 Visualization: Hendrik Satria Dwi Putra.
 Writing—original draft: Cheryn Ivana, Agustina Setiawati
 Writing—review & editing: Agustina Setiawati.

Competing Interests

There is no potential conflict of interest was reported by the authors.

Ethical Approval

Ethical approval was obtained from the Ethics Committee of the Faculty of Health Sciences, Respati University, Yogyakarta with approval number 051/FIKES/PL/III/2023.

Funding

This study was self-funded by the corresponding author and received no external financial support from any funding organization.

Supplementary File

Figure S1. Energy dispersive spectroscopy on the scanning electron microscope (EDS-SEM) of fabricated scaffold.

Table S1. Result of energy dispersive spectroscopy (EDS) spectrum analysis.

References

- Levengood SL, Zhang M. Chitosan-based scaffolds for bone tissue engineering. *J Mater Chem B* 2014;2(21):3161-84. doi:10.1039/c4tb00027g
- Rosa N, Moura MF, Olhero S, Simoes R, Magalhães FD, Marques AT, et al. Bone: an outstanding composite material. *Appl Sci* 2022;12(7):3381. doi:10.3390/app12073381
- Sheikh Z, Najeeb S, Khurshid Z, Verma V, Rashid H, Glogauer M. Biodegradable materials for bone repair and tissue engineering applications. *Materials (Basel)* 2015;8(9):5744-94. doi:10.3390/ma8095273
- Estévez M, Batoni E, Cicuéndez M, Bonatti AF, Fernández-Marcelo T, De Maria C, et al. Fabrication of 3D biofunctional magnetic scaffolds by combining fused deposition modelling and inkjet printing of superparamagnetic iron oxide nanoparticles. *Tissue Eng Regen Med* 2025;22(5):627-46. doi:10.1007/s13770-025-00711-2
- Cahyaningrum SE, Amaria, Ramadhan MI, Herdyastuti N. Synthesis hydroxyapatite/collagen/chitosan composite as bone graft for bone fracture repair. In: International Joint Conference on Science and Engineering (IJCSSE 2020). Atlantis Press; 2020. p. 337-41. doi:10.2991/aer.k.201124.061
- Lichte P, Pape HC, Pufe T, Kobbe P, Fischer H. Scaffolds for bone healing: concepts, materials and evidence. *Injury* 2011;42(6):569-73. doi:10.1016/j.injury.2011.03.033
- Yunus Basha R, Sampath Kumar TS, Doble M. Design of biocomposite materials for bone tissue regeneration. *Mater Sci Eng C Mater Biol Appl* 2015;57:452-63. doi:10.1016/j.msec.2015.07.016
- Turnbull G, Clarke J, Picard F, Riches P, Jia L, Han F, et al. 3D bioactive composite scaffolds for bone tissue engineering. *Bioact Mater* 2018;3(3):278-314. doi:10.1016/j.bioactmat.2017.10.001
- Ressler A. Chitosan-based biomaterials for bone tissue engineering applications: a short review. *Polymers (Basel)* 2022;14(16):3430. doi:10.3390/polym14163430
- Saravanan S, Leena RS, Selvamurugan N. Chitosan based biocomposite scaffolds for bone tissue engineering. *Int J Biol Macromol* 2016;93(Pt B):1354-65. doi:10.1016/j.ijbiomac.2016.01.112
- Fraile-Martínez O, García-Montero C, Coca A, Álvarez-Mon MA, Monserrat J, Gómez-Lahoz AM, et al. Applications of polymeric composites in bone tissue engineering and jawbone regeneration. *Polymers (Basel)* 2021;13(19):3429. doi:10.3390/polym13193429
- Filippi M, Born G, Chaaban M, Scherberich A. Natural polymeric scaffolds in bone regeneration. *Front Bioeng Biotechnol* 2020;8:474. doi:10.3389/fbioe.2020.00474
- Setiawati A, Kencana NB, Putra HS, Kencana MV, Ajiteru O, Yoga IM, et al. Biomimetic chitosan-based scaffold for 3D breast cancer cell culture: a promising tool for anticancer drug screening. *Macromol Res* 2025;33(9):1149-62. doi:10.1007/s13233-025-00405-7
- Devi LC, Putra HS, Kencana NB, Olatunji A, Setiawati A. Turning *Portunus pelagicus* shells into biocompatible scaffolds for bone regeneration. *Biomedicines* 2024;12(8):1796. doi:10.3390/biomedicines12081796
- Setiawati A, Trichahya K, Dika Octa Riswanto F, Dwiatmaka Y. Towards a sustainable chitosan-based composite scaffold derived from *Scylla serrata* crab chitosan for bone tissue engineering. *J Biomater Sci Polym Ed* 2024;35(2):146-63. doi:10.1080/09205063.2023.2271263
- Vidal JL, Jin T, Lam E, Kerton F, Moores A. Blue is the new green: valorization of crustacean waste. *Curr Res Green Sustain Chem* 2022;5:100330. doi:10.1016/j.crgsc.2022.100330
- Fatmah N, Azizah D, Cahyani MD. Synthesis of chitosan from crab's shell waste (*Portunus pelagicus*) in mertasinga-cirebon. In: International Conference on Progressive Education (ICOPE 2019). Atlantis Press; 2020. p. 370-5. doi:10.2991/assehr.k.200323.152
- Mohan K, Muralisankar T, Jayakumar R, Rajeevgandhi C. A study on structural comparisons of α -chitin extracted from marine crustacean shell waste. *Carbohydr Polym Technol Appl* 2021;2:100037. doi:10.1016/j.carpta.2021.100037
- Dawson J, Schussler O, Al-Madhoun A, Menard C, Ruel M, Skerjanc IS. Collagen scaffolds with or without the addition of RGD peptides support cardiomyogenesis after aggregation of mouse embryonic stem cells. *In Vitro Cell Dev Biol Anim* 2011;47(9):653-64. doi:10.1007/s11626-011-9453-0
- Barczyk M, Carracedo S, Gullberg D. Integrins. *Cell Tissue Res* 2010;339(1):269-80. doi:10.1007/s00441-009-0834-6
- Setiawati A, Jeong S, Brilian AI, Lee SH, Shim JG, Jung KH, et al. Fabrication of a tailored, hybrid extracellular matrix composite. *Macromol Biosci* 2022;22(9):e2200106. doi:10.1002/mabi.202200106
- Kolb AD, Bussard KM. The bone extracellular matrix as an ideal milieu for cancer cell metastases. *Cancers (Basel)* 2019;11(7):1020. doi:10.3390/cancers11071020
- Kafi MA, Aktar MK, Phanny Y, Todo M. Adhesion, proliferation and differentiation of human mesenchymal stem cell on

- chitosan/collagen composite scaffold. *J Mater Sci Mater Med* 2019;30(12):131. doi:10.1007/s10856-019-6341-8
24. Azaman FA, Zhou K, Blanes-Martínez MDM, Brennan Fournet M, Devine DM. Bioresorbable chitosan-based bone regeneration scaffold using various bioceramics and the alteration of photoinitiator concentration in an extended UV photocrosslinking reaction. *Gels* 2022;8(11):696. doi:10.3390/gels8110696
 25. Sobczak-Kupiec A, Drabczyk A, Florkiewicz W, Głab M, Kudłacik-Kramarczyk S, Słota D, et al. Review of the applications of biomedical compositions containing hydroxyapatite and collagen modified by bioactive components. *Materials (Basel)* 2021;14(9):2096. doi:10.3390/ma14092096
 26. Affecting F, Cooperative S, Bulletin S, Hood-Nowotny, Umana NH Najera, Inselbacher E, et al. © 1964. Nature Publishing Group 1964;Di(3):1-4.
 27. Xing F, Chi Z, Yang R, Xu D, Cui J, Huang Y, et al. Chitin-hydroxyapatite-collagen composite scaffolds for bone regeneration. *Int J Biol Macromol* 2021;184:170-80. doi:10.1016/j.ijbiomac.2021.05.019
 28. Pendegress CJ, El-Husseiny M, Blunn GW. The development of fibronectin-functionalised hydroxyapatite coatings to improve dermal fibroblast attachment in vitro. *J Bone Joint Surg Br* 2012;94(4):564-9. doi:10.1302/0301-620x.94b4.27698
 29. Pallela R, Venkatesan J, Janapala VR, Kim SK. Biophysicochemical evaluation of chitosan-hydroxyapatite-marine sponge collagen composite for bone tissue engineering. *J Biomed Mater Res A* 2012;100(2):486-95. doi:10.1002/jbm.a.33292
 30. Budiraharjo R, Neoh KG, Kang ET. Hydroxyapatite-coated carboxymethyl chitosan scaffolds for promoting osteoblast and stem cell differentiation. *J Colloid Interface Sci* 2012;366(1):224-32. doi:10.1016/j.jcis.2011.09.072
 31. Chen Y, Huang Z, Li X, Li S, Zhou Z, Zhang Y, et al. In vitro biocompatibility and osteoblast differentiation of an injectable chitosan/nano-hydroxyapatite/collagen scaffold. *J Nanomater* 2012;2012(1):401084. doi:10.1155/2012/401084
 32. Fatima B. Quantitative analysis by IR: determination of chitin/chitosan DD. In: Khan M, do Nascimento GM, El-Azazy M, eds. *Modern Spectroscopic Techniques and Applications*. IntechOpen; 2020. doi:10.5772/intechopen.89708
 33. Czechowska-Biskup R, Jarońska D, Rokita B, Ułański P, Rosiak JM. Determination of degree of deacetylation of chitosan-comparison of methods. *Prog Chem Appl Chitin Deriv* 2012;17:5-20.
 34. Wang D, Zhang Y, Hong Z. Novel fast-setting chitosan/ β -dicalcium silicate bone cements with high compressive strength and bioactivity. *Ceram Inte* 2014;40(7 Pt A):9799-808. doi:10.1016/j.ceramint.2014.02.069
 35. Chung L, Maestas DR Jr, Housseau F, Elisseeff JH. Key players in the immune response to biomaterial scaffolds for regenerative medicine. *Adv Drug Deliv Rev* 2017;114:184-92. doi:10.1016/j.addr.2017.07.006
 36. Zhao H, Jin H, Cai J. Preparation and characterization of nano-hydroxyapatite/chitosan composite with enhanced compressive strength by urease-catalyzed method. *Mater Lett* 2014;116:293-5. doi:10.1016/j.matlet.2013.05.082
 37. Pandharipande SL, Bhagat PH. Synthesis of chitin from crab shells and its utilization in preparation of nanostructured film. *Int J Sci Eng Technol Res* 2016;5(5):1378-83.
 38. Das A, Ghosh S, Pramanik N. Chitosan biopolymer and its composites: processing, properties and applications - a comprehensive review. *Hybrid Adv* 2024;6:100265. doi:10.1016/j.hybadv.2024.100265
 39. Yusharani MS, Stenley, Harmami, Ulfin I, Ni'mah YL. Synthesis of water-soluble chitosan from squid pens waste as raw material for capsule shell: temperature deacetylation and reaction time. *IOP Conf Ser Mater Sci Eng* 2019;509(1):012070. doi:10.1088/1757-899x/509/1/012070
 40. Chonanant C, Chancharoen P, Kiatkulanusorn S, Luangpon N, Klarod K, Surakul P, et al. Biocomposite scaffolds based on chitosan extraction from shrimp shell waste for cartilage tissue engineering application. *ACS Omega* 2024;9(38):39419-29. doi:10.1021/acsomega.4c02910
 41. Šimat V, Rathod NB, Čagalj M, Hamed I, Generalić Mekinić I. Astaxanthin from crustaceans and their byproducts: a bioactive metabolite candidate for therapeutic application. *Mar Drugs* 2022;20(3):206. doi:10.3390/md20030206
 42. Muthu M, Gopal J, Chun S, Devadoss AJP, Hasan N, Sivanesan I. Crustacean waste-derived chitosan: antioxidant properties and future perspective. *Antioxidants (Basel)* 2021;10(2):228. doi:10.3390/antiox10020228
 43. Mathaba M, Daramola MO. Effect of chitosan's degree of deacetylation on the performance of pes membrane infused with chitosan during AMD treatment. *Membranes (Basel)* 2020;10(3):52. doi:10.3390/membranes10030052
 44. Wiercigroch E, Szafraniec E, Czamara K, Pacia MZ, Majzner K, Kochan K, et al. Raman and infrared spectroscopy of carbohydrates: a review. *Spectrochim Acta A Mol Biomol Spectrosc* 2017;185:317-35. doi:10.1016/j.saa.2017.05.045
 45. Erickson AE, Lan Levensgood SK, Sun J, Chang FC, Zhang M. Fabrication and characterization of chitosan-hyaluronic acid scaffolds with varying stiffness for glioblastoma cell culture. *Adv Healthc Mater* 2018;7(15):e1800295. doi:10.1002/adhm.201800295
 46. Becerra J, Rodriguez M, Leal D, Noris-Suarez K, Gonzalez G. Chitosan-collagen-hydroxyapatite membranes for tissue engineering. *J Mater Sci Mater Med* 2022;33(2):18. doi:10.1007/s10856-022-06643-w
 47. Rahman MS, Rana MM, Spitzhorn LS, Akhtar N, Hasan MZ, Choudhury N, et al. Fabrication of biocompatible porous scaffolds based on hydroxyapatite/collagen/chitosan composite for restoration of defected maxillofacial mandible bone. *Prog Biomater* 2019;8(3):137-54. doi:10.1007/s40204-019-0113-x
 48. Flores-Jiménez MS, Garcia-Gonzalez A, Fuentes-Aguilar RQ. Review on porous scaffolds generation process: a tissue engineering approach. *ACS Appl Bio Mater* 2023;6(1):1-23. doi:10.1021/acsbm.2c00740
 49. Chen Z, Du T, Tang X, Liu C, Li R, Xu C, et al. Comparison of the properties of collagen-chitosan scaffolds after γ -ray irradiation and carbodiimide cross-linking. *J Biomater Sci Polym Ed* 2016;27(10):937-53. doi:10.1080/09205063.2016.1169478
 50. Seyed MA, Vijayaraghavan K. Evaluation of an improved chitosan scaffold cross-linked with polyvinyl alcohol and amine coupling through 1-ethyl-3-(3-dimethyl aminopropyl)-carbodiimide (EDC) and 2 N-hydroxysuccinimide (NHS) for corneal applications. *Open Access Maced J Med Sci* 2018;6(9):1561-70. doi:10.3889/oamjms.2018.322
 51. Sun T, Khan TH, Sultana N. Fabrication and in vitro evaluation of nanosized hydroxyapatite/chitosan-based tissue engineering scaffolds. *J Nanomater* 2014;2014(1):194680. doi:10.1155/2014/194680
 52. Agarwal T, Narayan R, Maji S, Behera S, Kulanthaivel S, Maiti TK, et al. Gelatin/Carboxymethyl chitosan-based scaffolds for dermal tissue engineering applications. *Int J Biol Macromol* 2016;93(Pt B):1499-506. doi:10.1016/j.ijbiomac.2016.04.028
 53. Saxena V, Hasan A, Pandey LM. Antibacterial nano-biocomposite scaffolds of chitosan, carboxymethyl cellulose and Zn & Fe integrated hydroxyapatite (chitosan-CMC-FZO@HAp) for bone tissue engineering. *Cellulose* 2021;28(14):9207-26. doi:10.1007/s10570-021-04072-6
 54. Younes I, Rinaudo M. Chitin and chitosan preparation from marine sources. Structure, properties and applications. *Mar Drugs* 2015;13(3):1133-74. doi:10.3390/md13031133
 55. Elsabee MZ, Abdou ES. Chitosan based edible films and coatings: a review. *Mater Sci Eng C Mater Biol Appl*

- 2013;33(4):1819-41. doi:[10.1016/j.msec.2013.01.010](https://doi.org/10.1016/j.msec.2013.01.010)
56. Hwang YS, Cho J, Tay F, Heng JY, Ho R, Kazarian SG, et al. The use of murine embryonic stem cells, alginate encapsulation, and rotary microgravity bioreactor in bone tissue engineering. *Biomaterials* 2009;30(4):499-507. doi:[10.1016/j.biomaterials.2008.07.028](https://doi.org/10.1016/j.biomaterials.2008.07.028)
57. Sladkova M, de Peppo GM. Bioreactor systems for human bone tissue engineering. *Processes* 2014;2(2):494-525. doi:[10.3390/pr2020494](https://doi.org/10.3390/pr2020494)
58. Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. *J Cell Sci* 2006;119(Pt 19):3901-3. doi:[10.1242/jcs.03098](https://doi.org/10.1242/jcs.03098)
59. Damsky CH, Werb Z. Signal transduction by integrin receptors for extracellular matrix: cooperative processing of extracellular information. *Curr Opin Cell Biol* 1992;4(5):772-81. doi:[10.1016/0955-0674\(92\)90100-q](https://doi.org/10.1016/0955-0674(92)90100-q)
60. Ratri MC, Brilian AI, Setiawati A, Nguyen HT, Soum V, Shin K. Recent advances in regenerative tissue fabrication: tools, materials, and microenvironment in hierarchical aspects. *Adv Nanobiomed Res* 2021;1(5):2000088. doi:[10.1002/anbr.202000088](https://doi.org/10.1002/anbr.202000088)